Fundraising Fox
FlightPath
Birmingham, US · Founded 2019 · 3 employees on LinkedIn · 5 known investors
Find your way into FlightPath
Sign up to see every warm intro you have to FlightPath
- Paths you didn't know you had: your email and LinkedIn already hold routes to the FlightPath team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Flightpath Biosciences develops microbiome-sparing, pathogen-specific drug candidates to treat infection-associated diseases by selectively targeting harmful bacteria while preserving healthy microbial communities. The company focuses on small molecule therapeutics for chronic and complex diseases, particularly those linked to pathogenic bacteria such as Crohn's disease.
Founders & leadership
FlightPath was founded in 2019 by Matt Tindall.
Board
Investors · 5
How we know: the VCSheet dataset · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: WMU Biosciences Research & Commercialization Center's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.6M disclosed across 2 rounds · 2020–2023
▶$8.1MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
- Curtis ScribnerDirector
- Matthew TindallExecutive Officer, Director
- Cristina LarkinDirector
- Offering amount
- $9M
- Amount sold
- $8.1M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedDec 2021 · 1 investors · BiotechnologyRule 506(b)
- Mark P. de SouzaExecutive Officer, Director
- Curtis L. ScribnerExecutive Officer
- Matthew Charles TindallExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through FlightPath went on to found or lead other companies.
Frequently asked questions
- What does FlightPath do?
- Flightpath Biosciences develops microbiome-sparing, pathogen-specific drug candidates to treat infection-associated diseases by selectively targeting harmful bacteria while preserving healthy microbial communities. The company focuses on small molecule therapeutics for chronic and complex diseases, particularly those linked to pathogenic bacteria such as Crohn's disease.
- Who founded FlightPath?
- FlightPath was founded by Matt Tindall in 2019.
- Who are FlightPath's investors?
- FlightPath's investors include First In Ventures, ID Ventures, Michigan Rise, WMU Biosciences Research & Commercialization Center, Active Capital.
- How much funding has FlightPath raised?
- FlightPath has disclosed $9.6M raised across 2 rounds.
- Where is FlightPath headquartered?
- FlightPath is headquartered in Birmingham, US.